Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Neuland Laboratories Limited (NEULANDLAB) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.023x
Based on the latest financial reports, Neuland Laboratories Limited (NEULANDLAB) has a cash flow conversion efficiency ratio of -0.023x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹-367.47 Million) by net assets (₹16.20 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neuland Laboratories Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Neuland Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Neuland Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neuland Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Wendy’s Co
NASDAQ:WEN
|
0.590x |
|
Yellow Cake plc
OTCQX:YLLXF
|
-0.001x |
|
Guangdong Orient Zirconic Ind Sci & Tech Co Ltd
SHE:002167
|
0.092x |
|
Air France-KLM SA
PINK:AFRAF
|
1.455x |
|
Bomin Electronics Co Ltd
SHG:603936
|
0.009x |
|
ARB Corporation Ltd
AU:ARB
|
0.087x |
|
Lendlease Global Commercial REIT
PINK:LLGCF
|
0.020x |
|
Avino Silver & Gold Mines Ltd
NYSE MKT:ASM
|
0.046x |
Annual Cash Flow Conversion Efficiency for Neuland Laboratories Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Neuland Laboratories Limited from 2006 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹15.25 Billion | ₹3.17 Billion | 0.208x | +4.42% |
| 2024-03-31 | ₹12.83 Billion | ₹2.56 Billion | 0.199x | -16.93% |
| 2023-03-31 | ₹9.94 Billion | ₹2.39 Billion | 0.240x | +244.27% |
| 2022-03-31 | ₹8.41 Billion | ₹585.81 Million | 0.070x | -71.05% |
| 2021-03-31 | ₹7.86 Billion | ₹1.89 Billion | 0.241x | +198.11% |
| 2020-03-31 | ₹7.10 Billion | ₹573.41 Million | 0.081x | -19.21% |
| 2019-03-31 | ₹6.99 Billion | ₹699.07 Million | 0.100x | +395.08% |
| 2018-03-31 | ₹5.58 Billion | ₹112.68 Million | 0.020x | -71.52% |
| 2017-03-31 | ₹5.46 Billion | ₹386.81 Million | 0.071x | -70.48% |
| 2016-03-31 | ₹1.87 Billion | ₹448.26 Million | 0.240x | +194.71% |
| 2015-03-31 | ₹1.62 Billion | ₹131.72 Million | 0.081x | -77.18% |
| 2014-03-31 | ₹1.24 Billion | ₹443.82 Million | 0.357x | +39.32% |
| 2013-03-31 | ₹1.00 Billion | ₹256.77 Million | 0.256x | -60.26% |
| 2012-03-31 | ₹764.81 Million | ₹493.39 Million | 0.645x | +39.53% |
| 2011-03-31 | ₹739.68 Million | ₹341.98 Million | 0.462x | +109.13% |
| 2010-03-31 | ₹688.95 Million | ₹152.31 Million | 0.221x | -22.15% |
| 2009-03-31 | ₹758.08 Million | ₹215.28 Million | 0.284x | +186.68% |
| 2008-03-31 | ₹686.76 Million | ₹68.03 Million | 0.099x | +218.14% |
| 2007-03-31 | ₹596.77 Million | ₹-50.04 Million | -0.084x | -151.12% |
| 2006-03-31 | ₹523.07 Million | ₹85.81 Million | 0.164x | -- |